Sign In
Buy ITOS
$10.15
+0 (+0%)
At Close: Nov 28, 2025
iTeos Announces First Patient Dosed in GALAXIES Lung-301 Phase 3 Study, Earning $35 Million in Milestones from GSK
07:00am, Monday, 08'th Jul 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, July 08, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical company pioneering the discovery an
iTeos Therapeutics to raise $120 million via registered direct offering
09:45am, Friday, 10'th May 2024
iTeos Therapeutics Inc (NASDAQ: ITOS) is up 30% today after announcing plans of a registered direct offering. iTeos Therapeutics stock pops on Q1 earnings The biotechnology company will sell a total
iTeos Reports First Quarter 2024 Financial Results and Provides Business Updates
08:26am, Friday, 10'th May 2024
- Belrestotug + dostarlimab exceeded pre-defined efficacy criteria for clinically relevant activity observed in an interim assessment of Phase 2 GALAXIES Lung-201 - Clinically meaningful tumor reducti
iTeos Therapeutics Announces $120 Million Registered Direct Offering
08:24am, Friday, 10'th May 2024
- Led by existing investors RA Capital Management and Boxer Capital - Purchase price of $17.50 represents a premium of approximately 44% to last close - Further strengthens balance sheet with pro form
WATERTOWN, Mass. and GOSSELIES, Belgium, April 07, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Appoints Oncology Veteran Jill DeSimone to Its Board of Directors
07:01am, Wednesday, 06'th Mar 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 06, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
07:00am, Wednesday, 06'th Mar 2024
- Multiple clinical milestones across portfolio anticipated in 2024, including two Phase 2 trials assessing belrestotug + dostarlimab in 1L NSCLC and 1L HNSCC - Completed enrollment of third dose coho
WATERTOWN, Mass. and GOSSELIES, Belgium, March 05, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
iTeos to Participate in Upcoming Investor Conferences
07:00am, Friday, 01'st Mar 2024
WATERTOWN, Mass. and GOSSELIES, Belgium, March 01, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
Strength Seen in iTeos Therapeutics, Inc. (ITOS): Can Its 7.4% Jump Turn into More Strength?
07:16am, Monday, 26'th Feb 2024
iTeos Therapeutics, Inc. (ITOS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further stre
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
08:01am, Wednesday, 10'th Jan 2024
iTeos: Readouts From TIGIT And Adenosine Pathway Inhibitors Makes This A Must Watch
Wall Street Analysts Believe iTeos Therapeutics, Inc. (ITOS) Could Rally 243.43%: Here's is How to Trade
11:17am, Wednesday, 13'th Dec 2023
The consensus price target hints at a 243.4% upside potential for iTeos Therapeutics, Inc. (ITOS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in
Does iTeos Therapeutics, Inc. (ITOS) Have the Potential to Rally 283.59% as Wall Street Analysts Expect?
11:17am, Monday, 27'th Nov 2023
The average of price targets set by Wall Street analysts indicates a potential upside of 283.6% in iTeos Therapeutics, Inc. (ITOS). While the effectiveness of this highly sought-after metric is questi
iTeos to Present at the Piper Sandler 35th Annual Healthcare Conference
07:00am, Tuesday, 21'st Nov 2023
WATERTOWN, Mass. and GOSSELIES, Belgium, Nov. 21, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development
